Aditxt is a pre-revenue biotechnology holding company building a portfolio of health innovation subsidiaries, none of which have commercially approved products. The company operates through three core subsidiaries. Adimune is developing ADI (Apoptotic DNA Immunotherapy), a nucleic acid-based platform designed to retrain the immune system to tolerate specific tissues rather than broadly suppressing immune function. The lead candidate, ADI-100, targets autoimmune conditions including type-1 diabetes and psoriasis, with a Phase 1 trial at the Mayo Clinic expected to begin in 2026. Pearsanta is developing blood-based diagnostic tests using mitochondrial DNA biomarkers, with lead candidates targeting prostate cancer and endometriosis. Pearsanta operates a CLIA-certified, CAP-accredited lab in Richmond, VA, and intends to license distribution rights to U.S. and international partners once regulatory approval is obtained. Adivir is focused on antiviral and antimicrobial therapeutics but remains in early-stage portfolio building with no disclosed product candidates. Aditxt also established Adifem for a women's health strategy centered on acquiring Evofem Biosciences, but that deal was terminated in October 2025 after Evofem shareholders did not approve it. Aditxt's core IP is licensed: ADI from Loma Linda University, and Pearsanta's Mitomic platform was acquired from MDNA Life Sciences. With no product revenue, Aditxt funds operations entirely through capital raises.